Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessment of a Novel NeuroAI-powered Transcutaneous Neuromodulation Device in Alleviating Tremor Symptoms and Enhancing Quality of Life for Patients With Upper Limb Essential Tremor

NCT06235190 is registered in ClinicalTrials.gov with Fasikl Inc. as lead sponsor.

NCT NCT06235190
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06235190 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessment of a Novel NeuroAI-powered Transcutaneous Neuromodulation Device in Alleviating Tremor Symptoms and Enhancing Quality of Life for Patients With Upper Limb Essential Tremor
Lead sponsor
Fasikl Inc.
Phase
Not applicable
Overall status
Completed
Start date
February 27, 2024
Completion date
November 6, 2025
Enrollment
125 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

essential tremor